Multiple sclerosis and related disorders最新文献

{"title":"Sex differences in use of potentially teratogenic disease modifying treatments for multiple sclerosis and degree of hormonal contraception overlap in women between 2007–2021: An Australian population-based study","authors":"A. Fragkoudi ,&nbsp;A.R. Rumbold ,&nbsp;K.A. Hall ,&nbsp;J. Lechner-Scott ,&nbsp;J. Ilomäki ,&nbsp;L.E. Grzeskowiak","doi":"10.1016/j.msard.2024.105937","DOIUrl":"10.1016/j.msard.2024.105937","url":null,"abstract":"<div><h3>Background</h3><div>Disease modifying treatments (DMTs) for multiple sclerosis (MS) have varying levels of teratogenic potential, but whether this influences DMT prescribing patterns by sex or concurrent use of hormonal contraception in women is unknown. This study aimed to examine patterns in dispensing of DMTs in women and men with MS, and hormonal long-acting reversible contraceptive (LARC) overlap at DMT initiation among women.</div></div><div><h3>Methods</h3><div>Population cohort study using 10% random sample of the Australian Pharmaceutical Benefits Scheme dispensing data (2007–2021). DMT dispensing data were evaluated separately for women and men aged 18–49 years. Hormonal LARC overlap was determined by receipt of contraceptive dispensing where the expected duration of efficacy overlapped with the DMT dispensing date.</div></div><div><h3>Results</h3><div>DMTs with teratogenic potential (cladribine, sphingosine-1-phosphates and teriflunomide) were less likely to be commenced in women than men aged 18–39 (OR 0.70, 0.51–0.96), but not in those aged 40–49 (OR 0.93, 0.60–1.43). Hormonal LARC overlap was higher among those commenced DMTs with teratogenic potential compared with interferons (aOR 2.52, 1.14, 5.55).</div></div><div><h3>Conclusion</h3><div>Sex and age differences in DMT utilisation were observed based on teratogenic potential. Hormonal LARC overlap appears higher in those receiving potentially teratogenic DMTs, but overall rates remain low.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105937"},"PeriodicalIF":2.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving manual dexterity using ergonomic wearable glove in patients with multiple sclerosis: A quasi-randomized clinical trial","authors":"Laura Ciatto,&nbsp;Biagio Dauccio,&nbsp;Graziana Tavilla,&nbsp;Stefania Bartolomeo,&nbsp;Viviana Lo Buono,&nbsp;Maria Cristina De Cola,&nbsp;Angelo Quartarone,&nbsp;Concetta Pastura,&nbsp;Roberta Cellini,&nbsp;Mirjam Bonanno ,&nbsp;Rocco Salvatore Calabrò","doi":"10.1016/j.msard.2024.105938","DOIUrl":"10.1016/j.msard.2024.105938","url":null,"abstract":"<div><div>One main problem faced by people with multiple sclerosis (PwMS) is upper limb dysfunction, which can occur in the first decade of the disease and with the highest prevalence of disability in the progressive type of the disease. Then, PwMS may benefit from personalised and intensive treatment as provided by robotic devices. These innovative devices have increasingly been brought into the neurorehabilitation field, due to their ability to provide repetitive and task-oriented training. In this quasi-randomized study, we aim to evaluate the effects of robotic-assisted hand training, using the Hand TutorTM device, on hand functionality, active RoM, and manual dexterity, compared to conventional rehabilitation in PwMS. We enrolled 30 MS patients, who received 20 training sessions, each lasting 45 min with robotic-assisted hand training with Hand Tutor (n 15, experimental group) or conventional rehabilitation therapy (n 15, control group). All patients were evaluated at pre- and post-intervention with clinical scales for upper limb functionality (DASH, BBT, NHPT, and MI). In addition, only patients in the experimental group received an objective kinematic analysis of the hand and wrist movements, delivered by the Hand Tutor glove, both pre- and post-intervention. We found that PwMS in both groups statistically improved their upper limb functions, however the experimental group achieved better results in terms of manual dexterity. This promising rehabilitation training with Hand Tutor glove led to positive effects on upper limbs motor outcomes and kinematic parameters in patients with MS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105938"},"PeriodicalIF":2.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preceding hepatitis B virus infection is highly prevalent in patients with neuromyelitis optica spectrum disorder in Taiwan","authors":"Wen-Yu Ou Yang ,&nbsp;Yu-Shuen Tsai ,&nbsp;Yi-Hong Liu ,&nbsp;Yen-Feng Wang ,&nbsp;Cheng-Tsung Hsiao ,&nbsp;Kuan-Lin Lai ,&nbsp;Yi-Chung Lee ,&nbsp;Yi-Chu Liao","doi":"10.1016/j.msard.2024.105923","DOIUrl":"10.1016/j.msard.2024.105923","url":null,"abstract":"<div><h3>Background</h3><div>Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system, characterized by pathogenic anti-Aquaporin-4 antibodies (AQP4-Ab). Given that infections can trigger autoimmune responses, we investigated the association between Hepatitis B virus (HBV) infection and NMOSD.</div></div><div><h3>Methods</h3><div>HBV and hepatitis C virus serologies were analyzed in 105 NMOSD patients, 85 multiple sclerosis (MS) patients, and 1,661 healthy Taiwanese controls. Participants were classified into four HBV infection statuses (acute, chronic, resolved, and never infected), and further grouped by vaccination status. Logistic regression was used to estimate odds ratios (OR) for NMOSD development in individuals with chronic or resolved HBV infection.</div></div><div><h3>Results</h3><div>Among those born before the Taiwan's universal vaccination program, 63.4 % of NMOSD patients had resolved HBV infection, compared to 30.6 % of MS patients and 16.4 % of controls. Resolved HBV infection was associated with a 2.3-fold increased risk for NMOSD development (95 % CI, 1.4–3.8), but not with MS risk. In the post-vaccination cohort, resolved HBV infection remained more frequent in NMOSD patients (8.7 %) than in MS (0 %) and controls (1.8 %). NMOSD patients with resolved HBV infection had later disease onset by 14.6 years and higher Expanded Disability Status Scale (EDSS) scores compared to those without HBV infection, even after adjusting for age and sex (3.5 ± 1.9 vs. 2.2 ± 1.8, <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Preceding HBV infection is prevalent among Taiwanese NMOSD patients and is associated with increased disease risk, older age at onset, and greater disability. Screening for HBV is essential for NMOSD patients, particularly in endemic regions.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105923"},"PeriodicalIF":2.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of insurance status on MRI phenotypes in MS","authors":"Melissa Lynne Martin ,&nbsp;Timothy Robert-Fitzgerald ,&nbsp;Matthew K. Schindler ,&nbsp;Christopher Perrone ,&nbsp;Guy Schultz ,&nbsp;Selah Lynch ,&nbsp;Nebojsa Mirkovic ,&nbsp;Sunil Thomas ,&nbsp;Ameena Elahi ,&nbsp;Donovan Reid ,&nbsp;Tyler M. Moore ,&nbsp;Erica B. Baller ,&nbsp;Theodore D. Satterthwaite ,&nbsp;Matthew Cieslak ,&nbsp;Sydney Covitz ,&nbsp;Azeez Adebimpe ,&nbsp;Abigail Manning ,&nbsp;Clyde E. Markowitz ,&nbsp;John A. Detre ,&nbsp;Amit Bar-Or ,&nbsp;Russell T. Shinohara","doi":"10.1016/j.msard.2024.105919","DOIUrl":"10.1016/j.msard.2024.105919","url":null,"abstract":"<div><h3>Background</h3><div>Health insurance in the United States varies in coverage of essential diagnostic tests, therapies, and specialists. Health disparities between privately and publicly insured patients with MS have not been comprehensively assessed. The objective of this study is to evaluate the impact of public versus private insurance on longitudinal brain outcomes in MS.</div></div><div><h3>Methods</h3><div>Lesional, thalamic, and gray and white matter volumes were extracted from longitudinal MRI of 710 MS patients. Baseline volumes and atrophy rates of lesional, thalamic, and gray and white matter volumes were compared across insurance groups.</div></div><div><h3>Results</h3><div>After image quality assessment, 376 (284 private / 92 public), 638 (499 / 139), and 331 (250 / 81), patients were in MS lesion, thalamic, gray and white matter analyses respectively. Baseline lesion volume was higher for publicly insured patients but increased at a slightly higher rate in those privately insured (p = 0.01). Baseline gray matter measurements were lower for patients with public insurance, but thalamic (p &lt; 0.01) and gray matter (p &lt; 0.01) atrophy rates were slightly higher in the private insurance group.</div></div><div><h3>Conclusion</h3><div>Insurance type was associated with lesion, thalamic, and gray matter volumes. The results suggest that patients with public insurance may present with more advanced disease.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105919"},"PeriodicalIF":2.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting faller status in persons with multiple sclerosis using the Multiple Sclerosis Walking Scale-12","authors":"Caterina Abate ,&nbsp;Elizabeth S. Gromisch ,&nbsp;Marc Campo ,&nbsp;Jennifer A. Ruiz ,&nbsp;Heather M. DelMastro","doi":"10.1016/j.msard.2024.105924","DOIUrl":"10.1016/j.msard.2024.105924","url":null,"abstract":"<div><h3>Background</h3><div>Persons with multiple sclerosis (PwMS) are at an increased risk for falling, making it necessary to identify useful screening tools. The aims of this study were to 1) determine a cut-off score for the 12-item Multiple Sclerosis Walking Scale (MSWS-12) for identifying PwMS as fallers and 2) evaluate its predictive ability of faller status after controlling for other potential contributing factors.</div></div><div><h3>Methods</h3><div>Participant characteristics, MSWS-12, and falls in the last six months were collected on PwMS (n = 171) during a single session. Fallers (53.8 %; n = 92) were individuals reporting ≥ 1 fall in the past six months. A receiver-operating-characteristic (ROC) curve was performed to estimate the classification accuracy (area under the curve; AUC) of the MSWS-12 at detecting fallers. Optimal cut-off scores were calculated using the Youden Index and Index of Union methods. The dichotomized MSWS-12 cut-off score was then entered into a logistic regression, with faller status as the outcome, and age, gender, body mass index, disease duration, and fatigue as covariates.</div></div><div><h3>Results</h3><div>The MSWS-12 had a fair classification accuracy for identifying fallers (AUC = 0.74), with the cut-off score of ≥ 46 % having 76.1 % sensitivity and 64.6 % specificity. The MSWS-12 cut-off score remained a significant predictor of faller status in the adjusted model (adjusted odds ratio [aOR]: 3.77, 95 % CI: 1.75, 8.15, <em>P</em> = .001), along with higher fatigue (aOR: 1.11, 95 % CI: 1.02, 1.20, <em>P</em> = .015).</div></div><div><h3>Conclusion</h3><div>PwMS with MSWS-12 scores ≥ 46 % were more likely to be fallers than those with lower scores. When used in conjunction with a clinician's judgement and other assessments, the MSWS-12 may be a useful screening tool for identifying PwMS who are fallers.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105924"},"PeriodicalIF":2.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is sedentary behavior associated with body composition in multiple sclerosis?","authors":"Brenda Jeng ,&nbsp;Robert W. Motl","doi":"10.1016/j.msard.2024.105922","DOIUrl":"10.1016/j.msard.2024.105922","url":null,"abstract":"<div><h3>Background</h3><div>To date, the evidence regarding the relationship between sedentary behavior and weight status based on body mass index in multiple sclerosis (MS) has not been definitive, and the conflicting results may be associated with the approaches for measurement of sedentary behavior and body composition.</div></div><div><h3>Objective</h3><div>The current study examined the relationship between device-based sedentary time and body composition outcomes derived from dual-energy x-ray absorptiometry (DXA) in persons with MS, controlling for age, sex, disability status, and physical activity as covariates of both outcomes in MS.</div></div><div><h3>Methods</h3><div>Persons with MS were recruited based on body mass index categories for a full range of body composition scores. Participants (n = 62) completed a DXA scan and wore an accelerometer on a belt for a 7-day period.</div></div><div><h3>Results</h3><div>Sedentary time was not associated with percent fat mass (<em>pr_s</em> = –.13, <em>p</em> = .36), lean mass (<em>pr_s</em> = .11, <em>p</em> = .40), bone mineral content (<em>pr_s</em> = –.03, <em>p</em> = .80), or bone mineral density (<em>pr_s</em> = –.21, <em>p</em> = .11).</div></div><div><h3>Conclusions</h3><div>Time spent in sedentary behavior was not significant correlated with body composition outcomes in our sample of persons with MS. These results support the consideration of other outcomes of sedentary behavior as well as other predictors of body composition over-and-beyond sedentary behavior.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105922"},"PeriodicalIF":2.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)","authors":"Cécile Donzé ,&nbsp;Claude Mekies ,&nbsp;Géraud Paillot ,&nbsp;Patrick Vermersch ,&nbsp;Guillaume Montagu ,&nbsp;Lucie Brechenmacher ,&nbsp;Alexandre Civet ,&nbsp;David Pau ,&nbsp;Catherine Mouzawak ,&nbsp;Mikael Cohen","doi":"10.1016/j.msard.2024.105925","DOIUrl":"10.1016/j.msard.2024.105925","url":null,"abstract":"<div><h3>Background</h3><div>In multiple sclerosis (MS), the measure of the loss of autonomy appears to be particularly relevant to provide adapted and personalized responses to improve the quality of care in routine clinical practice. In this context, this research aimed to develop a new patient-reported outcome measure (PROM) evaluating MS patients’ autonomy, in order to provide an easy-to-use tool in the context of the relations between healthcare professionals and patients with MS, and to be used in future clinical trials for treatment assessment.</div></div><div><h3>Methods</h3><div>This research was conducted in two consecutive stages. First, a preliminary questionnaire was generated using an innovative sociological approach for MS (after literature review, patient interviews, experts’ opinion, and patient focus groups). This questionnaire was then completed by patients with MS, before the reduction of the scale while maintaining relevant information, using a principal component analysis. The internal consistency reliability was assessed using the Cronbach's alpha coefficient. The external validity was evaluated using an analysis of variance to estimate the relation between the reduced questionnaire dimension scores and disease severity classes assessed by the SymptoMScreen questionnaire.</div></div><div><h3>Results</h3><div>The first qualitative step of the research led to provide a definition of disease-related autonomy as perceived by patients (to be able to carry out the roles the patient thinks the most important whether or not he/she receives assistance) as well as an associated taxonomy. On this basis, a preliminary questionnaire of 131 items grouped into 13 social dimensions was generated (seven dimensions with 63 questions concerning all the patients, and six dimensions with 68 questions concerning specific patients). This questionnaire was completed on a web platform by 653 analyzable patients with MS. Their main characteristics were as follows: female patients: 83.6 %, mean age at MS diagnosis: 34.8 ± 10.5 years, age ≥40 years at data collection: 68.1 %, MS duration ≥5 years: 68.4 %, severe MS (SymptoMScreen score ≥30): 36.8 %. On the basis on completed 131-item questionnaires, it was reduced in a 36-item short form of 10 social dimensions (five dimensions with 19 questions concerning all the patients, and five dimensions with 17 questions concerning specific patients). The internal consistency of the final questionnaire was good for all the dimensions, as the Cronbach's alpha coefficient ranged from 0.77 to 0.85 depending on dimensions. The construct validity of the questionnaire was also confirmed.</div></div><div><h3>Conclusion</h3><div>Our research allowed to build the first PROM designed to evaluate the autonomy of patients suffering from MS: the Multiple Sclerosis Autonomy Scale (MSAS). A confirmatory study, conducted in patients with MS using this validated questionnaire, is currently conducted.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105925"},"PeriodicalIF":2.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma levels of polyunsaturated fatty acids and multiple sclerosis susceptibility in a US case-control study","authors":"Eleanor Dunlop ,&nbsp;Alison Daly ,&nbsp;Trevor A. Mori ,&nbsp;Annette Langer-Gould ,&nbsp;Gavin Pereira ,&nbsp;Lucinda J. Black","doi":"10.1016/j.msard.2024.105920","DOIUrl":"10.1016/j.msard.2024.105920","url":null,"abstract":"<div><h3>Background</h3><div>There are plausible mechanisms, yet mixed evidence, that higher polyunsaturated fatty acids (PUFAs) levels reduces the risk of multiple sclerosis (MS). Prior studies relied on dietary surveys to estimate levels.</div></div><div><h3>Objective</h3><div>We tested associations between plasma levels of <em>n</em>-3 and <em>n</em>-6 PUFAs and likelihood of MS onset or clinically isolated syndrome (CIS) using data from the MS Sunshine Study, a case-control study conducted in the United States.</div></div><div><h3>Methods</h3><div>Case participants (<em>n</em> = 589) aged ≥ 18 years and matched control participants (<em>n</em> = 630) were recruited between 2011 and 2015. Plasma phospholipid fatty acid profiling was conducted by gas-liquid chromatography. We used logistic regression to report odds ratios, testing for interactions, adjusting for covariates and correcting for multiple comparisons.</div></div><div><h3>Results</h3><div>There was a 6 % lower probability of MS/CIS per unit increase in total <em>n</em>-6 PUFA level, expressed as a percentage of total plasma phospholipid fatty acids (odds ratio = 0.94; 95 % confidence interval = 0.90,0.98; <em>p</em> = 0.012). We found no statistically significant association between individual or total plasma levels of <em>n</em>-3 PUFAs and probability of MS/CIS; however, plasma levels of <em>n</em>-3 PUFAs were low across the cohort. No other individual or aggregate PUFA levels were significantly associated with MS/CIS.</div></div><div><h3>Conclusion</h3><div>A higher total <em>n</em>-6 PUFA level may be beneficial in terms of MS susceptibility.</div><div>Further research is needed to determine whether <em>n</em>-3 PUFAs may be beneficial only above a threshold that is achievable by supplementation.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105920"},"PeriodicalIF":2.9,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis","authors":"P. Kusnierova ,&nbsp;K․Zondra Revendova ,&nbsp;K. Karasova ,&nbsp;D. Zeman ,&nbsp;R. Bunganic ,&nbsp;P. Hradilek ,&nbsp;O. Volny ,&nbsp;A. Ganesh ,&nbsp;I. Kovacova ,&nbsp;D. Stejskal","doi":"10.1016/j.msard.2024.105915","DOIUrl":"10.1016/j.msard.2024.105915","url":null,"abstract":"<div><h3>Aims</h3><div>The aim of this study was to evaluate the association of serum neurofilament heavy chain (sNfH) and chitinase 3-like 1 (sCHI3L1) with treatment response and disease activity in multiple sclerosis (MS).</div></div><div><h3>Methods</h3><div>This single-center, prospective, observational cohort study was conducted at the MS Centre, University Hospital Ostrava, Czech Republic, from May 2020 to August 2023. sNfH and sCHI3L1 were determined using ELISA. A mixed-effects linear model with a log-transformed outcome variable was applied.</div></div><div><h3>Results</h3><div>We analyzed 459 samples from 57 people with MS. Patients were sampled an average of 8.05 times during 21.9 months of follow-up. Those experiencing a relapse at sampling had a sNfH concentration 50 % higher than those in remission (exp(β) 1.5, 95 % CI 1.15–1.96). A longer duration of treatment was associated with lower sNfH (exp(β) 0.95, 95 % CI 0.94–0.96). Patients switched from low- to high-efficacy disease-modifying therapies (DMTs) had higher sNfH than patients treated with low-efficacy DMTs only (exp(β) 1.95, 95 % CI 1.35–2.81). Higher sCHI3L1 was associated with older age (exp(β) 1.01, 95 % CI 1.00–1.02) and longer DMT use (exp(β) 1.01, 95 % CI 1.00–1.02). sCHI3L1 values were not associated with relapse at the time of sampling, renal function, sex, or type of DMT.</div></div><div><h3>Conclusion</h3><div>In contrast to sCHI3L1, sNfH may be a potential biomarker for monitoring treatment response and confirming clinical relapse in MS. Further research is needed to determine the long-term dynamics of sNfH and develop related treatment strategies.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"91 ","pages":"Article 105915"},"PeriodicalIF":2.9,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FROM BENCH TO BEDSIDE: A SNAIL IN TREACLE?","authors":"Christopher H Hawkes ,&nbsp;Gavin Giovannoni ,&nbsp;Jeanette Lechner-Scott ,&nbsp;Michael Levy ,&nbsp;Ann Yeh","doi":"10.1016/j.msard.2024.105916","DOIUrl":"10.1016/j.msard.2024.105916","url":null,"abstract":"","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"91 ","pages":"Article 105916"},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}